A Bioactive Synthetic Outer-Core Oligosaccharide Derived from a Klebsiella pneumonia Lipopolysaccharide for Bacteria
Dushen Chen1, Akhilesh K Srivastava2, Justyna Dubrochowska1
1Department of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, The Netherlands.
Abstract:
There is an urgent need for new treatment options for carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae), which is a common cause of life-threatening hospital- and community-acquired infections. Prophylactic or therapeutic vaccination may offer an approach to control these infections, however, none has yet been approved for human use. Here, we report the chemical synthesis of an outer core tetra- and pentasaccharide derived from the lipopolysaccharide of K. pneumoniae. The oligosaccharides were equipped with an aminopentyl linker, which facilitated conjugation to the carrier proteins CRM197 and BSA. Mice immunized with the glycoconjugate vaccine candidates elicited antibodies that recognized isolated LPS as well as various strains of K. pneumoniae. The successful preparation of the oligosaccharides relied on the selection of monosaccharide building blocks equipped with orthogonal hydroxyl and amino protecting groups. It allowed the differentiation of three types of amines of the target compounds and the installation of a crowded 4,5-branched Kdo moiety.
Insights
New glycoconjugate vaccines targeting carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae) were synthesized. Immunization in mice produced antibodies recognizing K. pneumoniae, offering a potential new strategy against these dangerous infections.
Area of Science:
- Microbiology
- Immunology
- Synthetic Chemistry
Background:
- Carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae) poses a significant threat, causing severe hospital- and community-acquired infections.
- Existing treatment options are limited, highlighting the urgent need for novel therapeutic strategies.
- Vaccination presents a promising avenue for controlling K. pneumoniae infections, but no approved vaccines are currently available.
Purpose of the Study:
- To chemically synthesize outer core oligosaccharides from K. pneumoniae lipopolysaccharide (LPS).
- To develop glycoconjugate vaccine candidates by linking synthesized oligosaccharides to carrier proteins.
- To evaluate the immunogenicity of these vaccine candidates in a mouse model.
Main Methods:
- Chemical synthesis of tetra- and pentasaccharides from K. pneumoniae LPS outer core.
- Attachment of an aminopentyl linker to the synthesized oligosaccharides.
- Conjugation of linker-equipped oligosaccharides to carrier proteins CRM197 and BSA.
- Immunization of mice with the resulting glycoconjugate vaccine candidates.
- Assessment of elicited antibody responses against K. pneumoniae LPS and various strains.
Main Results:
- Successful chemical synthesis of K. pneumoniae outer core tetra- and pentasaccharides.
- Development of glycoconjugate vaccines by conjugating oligosaccharides to CRM197 and BSA.
- Mice immunized with these candidates generated antibodies that recognized isolated LPS and multiple K. pneumoniae strains.
- The synthesis strategy effectively utilized orthogonal protecting groups for precise modification of monosaccharide building blocks.
Conclusions:
- The study successfully synthesized novel K. pneumoniae outer core oligosaccharides and developed promising glycoconjugate vaccine candidates.
- The developed vaccines elicited a robust antibody response in mice, demonstrating their potential for combating K. pneumoniae infections.
- This work provides a foundation for developing effective vaccines against carbapenem-resistant K. pneumoniae, addressing a critical unmet medical need.
Related Concept Videos
Formation of Lipopolysaccharides
Outer Layers of the Cell Envelope
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Peptidoglycan Synthesis
Bacterial Cell Wall
Biosynthesis of Lipids


